title: Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
abstract: OBJECTIVE
  Emtricitabine/tenofovir/rilpivirine as a single-tablet regimen (STR) is widely used without licence in treatment-experienced patients. The purpose of this retrospective observational study was to assess viral suppression of ART-experienced patients switching to STR.
  
  
  METHODS
  We assessed 131 pretreated patients switching to STR with HIV RNA <400 HIV-1 RNA copies/mL. The primary outcome measure was the proportion of patients at week 24 with HIV RNA <40 copies/mL.
  
  
  RESULTS
  By week 24, eight patients had stopped STR: four because of adverse events and four for other reasons. Three virological failures were observed; among these, at least one patient developed cross-resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs), in particular with the E138K pattern. In intent-to-treat analysis, 92% of participants (120 of 131) achieved HIV RNA <40 copies/mL. Only grade 1 to 2 adverse events were observed, mainly consisting of increased liver enzymes (n=33). Systemic exposure to rilpivirine was above the usually observed steady-state levels for the 18 measurements assessed.
  
  
  CONCLUSIONS
  Efficacy and tolerability are similar to those in treatment-naïve patients.
authors.affiliation: Le Trait d'Union, Center for HIV Infection Care, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
authors.forename: P
authors.initials: P
authors.lastname: Gantner
authors.forename: S
authors.initials: S
authors.lastname: Reinhart
authors.forename: M
authors.initials: M
authors.lastname: Partisani
authors.forename: M
authors.initials: M
authors.lastname: Baldeyrou
authors.forename: M-L
authors.initials: ML
authors.lastname: Batard
authors.forename: C
authors.initials: C
authors.lastname: Bernard-Henry
authors.forename: C
authors.initials: C
authors.lastname: Cheneau
authors.forename: E
authors.initials: E
authors.lastname: de Mautort
authors.forename: M
authors.initials: M
authors.lastname: Priester
authors.forename: S
authors.initials: S
authors.lastname: Fafi-Kremer
authors.forename: P
authors.initials: P
authors.lastname: Muret
authors.forename: D
authors.initials: D
authors.lastname: Rey
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015331:Cohort Studies; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004338:Drug Combinations; D057915:Drug Substitution; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage* / Q000009:adverse effects; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012367:RNA, Viral / Q000187:drug effects; D012189:Retrospective Studies; D000068696:Rilpivirine; D000068698:Tenofovir; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D009570:Nitriles; D063065:Organophosphonates; D011743:Pyrimidines; D012367:RNA, Viral; D003841:Deoxycytidine; D000068698:Tenofovir; D000068696:Rilpivirine; D000068679:Emtricitabine; D000225:Adenine
keywords: antiretroviral; efficacy; pharmacokinetic; rilpivirine; safety; single tablet regimen; switch